Corvus Pharmaceuticals (CRVS) reported second quarter 2026 results today, with a wider net loss and higher loss per share from continuing operations, giving investors fresh information to reassess the stock.

Corvus Pharmaceuticals has seen strong longer term momentum, with a year to date share price return of 90.16% and a very large 1 year total shareholder return of 222.97%. This comes even though the 30 day share price return is down 13.43% and the 90 day share price return is down 10.48% as investors digest today’s wider loss.

If this earnings update has you looking beyond Corvus Pharmaceuticals, it could be a good moment to scan other healthcare focused AI opportunities through our curated list of 43 healthcare AI stocks.

After a sharp run over the past year and a pullback around Corvus Pharmaceuticals’ wider loss, some investors may view this as a second chance, while others may prefer to wait. How does the current valuation compare with that trade off?

Most Popular Narrative: 60.2% Undervalued

Corvus Pharmaceuticals closed at $13.92, while the most followed narrative anchors on a fair value of $35. That gap rests on some very specific growth and margin assumptions.

The analysts have a consensus price target of $35.0 for Corvus Pharmaceuticals based on their expectations of its future earnings growth, profit margins and other risk factors.

However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $51.0, and the most bearish reporting a price target of just $27.0.

Read the complete narrative. Read the complete narrative.

Want to see what drives a fair value more than double today’s price? Revenue ramp assumptions, margin shifts and a steep future earnings multiple sit at the core of this narrative. The full breakdown also weighs a long runway discount rate against a company that currently has no revenue and is reporting losses.

Result: Fair Value of $35 (UNDERVALUED)

However, the Corvus Pharmaceuticals story still hinges on successful trial outcomes and future funding, since any clinical setback or dilutive capital raise could quickly challenge this valuation narrative.

Another View on Corvus Pharmaceuticals Valuation

The analyst fair value of $35 for Corvus Pharmaceuticals leans on future earnings power. On today’s numbers, the stock tells a different story. Corvus trades on a P/B of 5.2x, compared with 2.5x for the wider US biotechs group and 3.3x for peers, which points to a richer valuation on current balance sheet strength. How comfortable are you paying that kind of premium for a company that is still loss making?

See what the numbers say about this price in our valuation breakdown before you decide how to weigh those trade offs: See what the numbers say about this price — find out in our valuation breakdown.

That broader context is easier to see when you compare Corvus Pharmaceuticals directly with its sector on a simple chart:

Next Steps

Does the mix of risks and rewards around Corvus Pharmaceuticals leave you confident or cautious about the story from here? To pressure test that view against the underlying data and sentiment, take a closer look at the 1 key reward and 2 important warning signs

Looking for more investment ideas beyond Corvus Pharmaceuticals?

If Corvus Pharmaceuticals has sharpened your focus today, do not stop here. Use these targeted stock ideas to widen your watchlist before the next move.

• Zero in on potential bargains by scanning 51 high quality undervalued stocks that currently trade below what their fundamentals may justify.
• Prioritise resilience by reviewing 78 resilient stocks with low risk scores that score well on financial strength and volatility checks.
• Get ahead of the crowd by studying the screener containing 19 high quality undiscovered gems that combine quality fundamentals with lower market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.